New challenges in the clinical management of drug-resistant tuberculosis

Infectious Diseases in Clinical Practice

Volumn 11, Issue 6, 2002, Pages 329-339

  Mukherjee, Joia S ^a,b   Shin, Sonya ^a,b   Furin, Jennifer ^a,b   Rich, Michael L ^a   Léandre, Fernet ^a   Joseph, J Keith ^a   Seung, Kwonjune ^a   Acha, Julio ^c   Gelmanova, Irina ^d   Goncharova, Ekaterina ^d   Pasechnikov, Alexander ^d   Viru, Felix Alcántara ^c   Farmer, Paul ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c SOCIOS EN SALUD   (Peru)

^d PARTNERS IN HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; AMOXICILLIN PLUS CLAVULANIC ACID; CAPREOMYCIN; CIPROFLOXACIN; CLARITHROMYCIN; CLOFAZIMINE; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; GATIFLOXACIN; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; MOXIFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ABDOMINAL PAIN; ADULT; ALLERGY; ALOPECIA; ANXIETY DISORDER; ARTICLE; CHILD; COMORBIDITY; CONVULSION; DEPRESSION; DISEASE TRANSMISSION; DRUG EFFICACY; DRUG SENSITIVITY; EARLY DIAGNOSIS; ELECTROLYTE DISTURBANCE; EPIDEMIC; FEMALE; GASTROINTESTINAL DISEASE; GROWTH RETARDATION; GYNECOMASTIA; HAITI; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOKALEMIA; HYPOMAGNESEMIA; HYPOTHYROIDISM; IMPOTENCE; INSOMNIA; LIVER TOXICITY; LUNG RESECTION; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALABSORPTION; MALE; MORTALITY; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; NEPHROTOXICITY; NEURITIS; OTOTOXICITY; PERSONALITY DISORDER; PERU; PREGNANCY COMPLICATION; PSYCHOSIS; RASH; RUSSIAN FEDERATION; SIDE EFFECT; STOMACH DISEASE; STRAIN IDENTIFICATION; SURGICAL APPROACH; SURGICAL TECHNIQUE; TASTE DISORDER; TREATMENT OUTCOME; TREMOR; TUBERCULOSIS; UNITED STATES; VERTIGO; VESTIBULAR DISORDER;

EID: 0038318791     PISSN: 10569103     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.idc.0000078749.71576.0d     Document Type: Article

References (51)

1. Raviglione MC, Snider DE Jr, Kochi A. Global epidemiology of tuberculosis: morbidity and mortality of a worldwide epidemic. JAMA. 1995;273:220-226.
2. World Health Organization. Global Tuberculosis Control: WHO Report 1999. Geneva: World Health Organization; 1999. WHO/CDS/CPC/TB/99.259.
3. World Health Organization, International Union Against Tuberculosis and Lung Disease. Anti-Tuberculosis Drug Resistance in the World: the WHO/IUATLD Global Project on Anti-tuberculosis Drug Resistance Surveillance 1994-1997. Geneva: World Health Organization; 1997. WHO/TB/97.229.
4. World Health Organization. Anti-Tuberculosis Drug Resistance in the World: Report No. 2. The WHO/IUATLD Global Project on Anti-tuberculosis Drug Resistance Surveillance 2000. Geneva: World Health Organization; 2000. WHO/CDS/TB/2000.278.
5. Agerton TB, Valway SE, Blinkhorn RJ, et al. Spread of strain W, a highly drug-resistant strain of Mycobacterium tuberculosis, across the United States. Clin Infect Dis. 1999;29:85-92; discussion 93-5.
6. Centers for Disease Control and Prevention. Reported Tuberculosis in the United States, 2001. Atlanta, GA: Centers for Disease Control and Prevention; 2002.
7. Geiter L, ed., and Institute of Medicine. Ending Neglect: the Elimination of Tuberculosis in the United States. Washington, DC: National Academy Press; 2000.
8. Kimmerling ME, Kluge H, Vezhnina N, et al. Inadequacy of the current WHO re-treatment regimen in a central Siberian prison: treatment failure and MDR-TB. Int J Tuberc Lung Dis. 1999;3:451-453.
9. Espinal MA, Kim SJ, Suarez PG, et al. Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries. JAMA. 2000;283:2575-2576.
10. Farmer PE, Bayona J, Becerra MC, et al. The dilemma of MDR-TB in the global era. Int J Tuberc Lung Dis. 1998;2:869-876.
11. Rouillon A, Perdrizet S, Parrot R. Transmission of tubercle bacilli: the effects of chemotherapy. Tubercle. 1976;57:275-299.
12. Loudon RG, Spohn SK. Cough frequency and infectivity in patients with pulmonary tuberculosis. Am Rev Respir Dis. 1969;99:109-111.
13. Farmer PE, Bayona J, Becerra MC, et al. Poverty, inequality, and drug resistance: meeting community needs. In: Proceedings of International Union Against Tuberculosis and Lung Disease North American Region Conference. Feb. 27-Mar. 2, 1997;88-101.
14. Farmer P, Furin J, Shin S. Managing multidrug-resistant tuberculosis. J Respir Dis. 2000;21:53-56.
15. Rastogi NV, Labrousse V, Gohks. In vitro activity of 14 antimicrobial agents against drug susceptible and resistant clinical isolates of Mycobacterium tuberculosis and comparative intracellular activities against the virulent H37Rv strain in human macrophages. Curr Microbiol. 1996;33:167-75.
16. Shah A, Bhagat R, Panchal N. Resistant tuberculosis: successful treatment with amikacin, ofloxacin, clofazimine and PAS. J Tuberc Lung Dis. 1993;74:644-667.
17. Tamas F. Use of amikacin and amoxicillin-clavulanic acid against Mycobacterium tuberculosis. Chest. 1993;104:323.
18. Mitnick C, Bayona J, Palacios E, et al. Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. N Engl J Med. 2003;348:119-128.
19. Kochi A. The global tuberculosis situation and the new control strategy of the World Health Organization. Tubercle. 1991;72:1-6.
20. Busillo CP, Lessnau KD, Sanjana V, et al. Multidrug resistant Mycobacterium tuberculosis in patients with human immunodeficiency virus infection. Chest. 1992;102:797-801.
21. Correa AG. Unique aspects of tuberculosis in the pediatric population. Clin Chest Med. 1997;18:89-98.
22. Jacobs RF, Starke JR. Tuberculosis in children. Med Clin North Am. 1993;77:1335-1351.
23. Pineda PR, Leung A, Muller NL, et al. Intrathoracic pediatric tuberculosis: a report of 202 cases. Tuberc Lung Dis. 1993;74:261-266.
24. Vallejo JG, Starke JR. Intrathoracic tuberculosis in children. Semin Respir Infect. 1996;11:184-195.
25. Swanson DS, Starke JR. Drug-resistant tuberculosis in pediatrics. Pediatr Clin North Am. 1995;42:553-81.
26. Brost B, Newman R. The maternal and fetal effects of tuberculosis therapy. Obstet Gynecol Clin North Am. 1997;24:659-673.
27. Hamadeh M, Glassroth J. Tuberculosis and pregnancy. Chest. 1992;101:1114-1120.
28. Pomerantz M, Brown JM. Surgery in the treatment of multidrug-resistant tuberculosis. Clin Chest Med. 1997;18:123-130.
29. Tahaoǧlu K, Törün T, Sevim T, et al. The treatment of multidrug-resistant tuberculosis in Turkey. N Engl J Med. 2001;345:170-174.
30. Farmer PE, Bayona J, Shin S, et al. Preliminary results of community-based MDR-TB treatment in Lima, Peru. Int J Tuberc Lung Dis. 1998;2:S371.
31. Farmer PE, Léandre F, Bayona J, et al. DOTS-Plus for the poorest of the poor: the Partners In Health experience in Haiti. Int J Tuberc Lung Dis. 2001;5:S257.
32. Furin JJ, Mitnick CD, Shin SS, et al. Occurrence of serious adverse effects in patients receiving community-based therapy for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2001;5(7):648-654.
33. Kennedy N, Ramsey A, Viso L. Nutritional status and weight gain in patients with pulmonary tuberculosis in Tanzania. Trans Roy Soc Trop Med Hyg. 1996;90:162-166.
34. Holmes AM, Hesling CM, Wilson TM. Capreomycin-induced serum electrolyte abnormalities. Thorax. 1970;25:608-611.
35. Bar RS, Wilson HE, Mazzaferri EL. Hypomagnesemic hypocalcemia secondary to renal magnesium wasting. Ann Intern Med. 1975;82:646-649.
36. Shah GM, Kirschenbaum MA. Renal magnesium wasting associated with therapeutic agents. Miner Electrolyte Metab. 1991;17:58-64.
37. Sanford JP, Gilbert DN, Sande MA. The Sanford Guide to Antimicrobial Therapy. Dallas: Antimicrobial Therapy, Inc.; 1995.
38. Guillemin I, Jarlier V, Cambau E. Correlation between quinolone susceptibility patterns and sequences in the A and B subunits of DNA gyrase in mycobacteria. Antimicrob Agents Chemother. 1998;42:2084-2088.
39. Zhao X, Xu C, Domagala J, et al. DNA topoisomerase targets of the fluoroquinolones: a strategy for avoiding bacterial resistance. Proc Natl Acad Sci. 1997;94:13991-1396.
40. Portaels F, Rigouts L, Bastian I. Addressing multidrug-resistant tuberculosis in penitentiary hospitals and in the general population of the former Soviet Union. Int J Tuberc Lung Dis. 1999;3:582-588.
41. Passannante MR, Gallagher CT, Reichman LB. Preventive therapy for contacts of multidrug-resistant tuberculosis: a Delphi survey. Chest. 1994;106:431-434.
42. Jarvis WR. Nosocomial transmission of multidrug-resistant TB. Am J Infect Control. 1995;23:146-151.
43. Ritacco V, Di Leonardo M, Reniero A, et al. Nosocomial spread of human immunodeficiency virus-related multidrug-resistant tuberculosis in Buenos Aires. J Infect Dis. 1997;176:637-642.
44. Edlin BR, Tokars JI, Grieco MH, et al. An outbreak of multidrug-resistant tuberculosis among hospitalized patients with the acquired immunodeficiency syndrome. N Engl J Med. 1992;326:1514-1521.
45. Centers for Disease Control and Prevention. Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care facilities, 1994. MMWR Morb Mortal Wkly Rep. 1994;43:1-132.
46. American College of Chest Physicians and the American Thoracic Society. Institutional control measures for tuberculosis in the era of multiple drug resistance: ACCP/ATS Consensus Conference. Chest. 1995;108:1690-1710.
47. NIOSH Guide to the Selection and Use of Particulate Respirators Certified Under 42 CFR 84. Cincinnati: National Institute for Occupational Safety and Health; JJS, CDC. 1996: i-ix, 1-22.
48. Management of persons exposed to multidrug-resistant tuberculosis. MMWR Morb Mortal Wkly Rep. 1992;41:61-71.
49. Moran GJ, McCabe F, Morgan MT, et al. Delayed recognition and infection control for tuberculosis patients in the emergency department. Ann Emerg Med. 1995;26:290-295.
50. Fennelly KP, Nardell EA. The relative efficacy of respirators and room ventilation in preventing occupational tuberculosis. Infect Control Hosp Epidemiol. 1998;19:754-759.
51. Willeke K, Oian Y. Tuberculosis control through respirator wear: performance of National Institute for Occupational Safety and Health-regulated respirators. Am J Infect Control. 1998;26:139-142.